The Gujarat Food and Drug Control Administration (FDCA) has designated 4,000 retail pharmacies to dispense anti-TB drugs to patients not covered under the Revised National Tuberculosis Program (RNTCP). These assigned pharmacies will stock and sell medicines for TB patients and help get patient’s details in an effective way.
Gujarat FDCA is also aiding National Rural Health Mission (NRHM) by sharing important details of the patients not covered under the government healthcare Program.
“Based on the information shared, NRHM takes up the case with the concerned District TB Officer which thusly, in turn, ensures that private TB patients fall under the government ambit,” informs Gujarat FDCA Commissioner Dr. HG Koshia.
There are around 37,650 wholesale and retail pharmacies in Gujarat. This will help to check prevalence TB in people who are not covered under Directly Observed Treatment, Short-Course (DOTS). RNTCP uses the World Health Organization (WHO) suggested DOTS strategy and reaches over a billion people in 632 areas or reporting units the country over.
The RNTCP is responsible for carrying out Government of India’s five years TB National Strategic Plans. Both diagnosis and treatment of TB are free with the RNTCP. India has the highest tuberculosis burden, accounting for nearly one-fourth of the global incidence.
Specialists advocate that there is a need to have epidemiological information on TB through a nationwide surveillance. Central Government is also upscaling sensitive diagnostic modalities the country over as part of its implementation research projects by utilizing Genexpert to get TB and Multi-Drug Resistant TB (MDR TB).
Genexpert is a molecular test which identifies the DNA in TB bacteria. It uses a sputum test and can give a result in less than 2 hours. Also, the proportion of MDR-TB among previously treated TB cases has exceeded 50% in several countries.
In 2006, extremely drug-resistant TB (XDR-TB) was reported in all regions of the world and was rapidly classified by World Health Organization (WHO) as a serious emerging threat to global public health.
Reports on medicines quality problems with their serious health repercussions appear to be on the increase, the exact magnitude of the problem is unknown.
Study of the quality of anti-tuberculosis medicines circulating in selected newly independent newly independent of the former Soviet Union in November 2011 by WHO states that since 2000, no country outside of Eastern Europe and Central Asia has reported proportions of MDR-TB among new cases exceeding 6% (for countries reporting in excess of 10 MDR-TB cases).